# IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

> **NCT00349934** · PHASE1 · COMPLETED · sponsor: **Immutep S.A.S.** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** IMP321

## Key facts

- **NCT ID:** NCT00349934
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2009-11
- **Final completion:** 2010-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2010-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349934, "IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00349934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*